क्लिनिकल ट्रायल रडार

Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following:

° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a)

Stage 3 or

ctDNA positive

° High-risk breast cancer

Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT),

Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative,

CPS-EG score ≥ 3,

CPS-EG score ≥2 w ith ypN+, or

Recurrence score ≥ 25

No evidence of disease

Age ≥ 18

Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy

Non-exercising (i.e., < 30 minutes of moderate and < 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry)

° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI.

Cleared for exercise participation as per screening clearance via PAR-Q+

Willingness to comply with all study-related procedures